Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 1, 2002, Pages 17-19

  Hansen, Steen Werner ^a  

^a Sundhedsstyrelsen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MIXTURE; FEMALE; HUMAN; LEUKOPENIA; NAUSEA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SHORT SURVEY; VOMITING;

EID: 0036171185     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31593     Document Type: Article

References (17)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
2. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
3. A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients randomised into the 3rd International Collaborative Ovarian Neoplasm Study (ICON)
4. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
5. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
6. Phase II study of gemcitabine (2′,2′ difluorodeoxycytidine) in previously treated ovarian cancer patients
7. Prolonged oral etoposide as second-line therapy for platinum-resistent and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology group study
8. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Trials Group study
9. Epirubicin/paclitaxel/carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of an AGO-GINECO Intergroup phase III trial
10. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC)
11. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel
12. A phase II study of gemcitabine in platinum pretreated patients with advanced epithelial ovarian cancer
13. Phase II study of gemcitabine in ovarian cancer
14. Combination chemotherapy with platinum paclitaxel, and gemcitabine in patients with relapsed ovarian cancer
15. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV
16. A phase I intra & interpatient dose ranging trial of gemcitabine, carboplatin and paclitaxel (GCP) in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma
17. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer